U.S. markets open in 6 hours 42 minutes
  • S&P Futures

    3,815.75
    -18.25 (-0.48%)
     
  • Dow Futures

    30,805.00
    -131.00 (-0.42%)
     
  • Nasdaq Futures

    11,749.25
    -59.25 (-0.50%)
     
  • Russell 2000 Futures

    1,731.20
    -10.50 (-0.60%)
     
  • Crude Oil

    100.07
    +0.57 (+0.57%)
     
  • Gold

    1,764.40
    +0.50 (+0.03%)
     
  • Silver

    18.97
    -0.15 (-0.79%)
     
  • EUR/USD

    1.0269
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    2.8090
    0.0000 (0.00%)
     
  • Vix

    27.54
    +0.01 (+0.04%)
     
  • GBP/USD

    1.1953
    +0.0001 (+0.01%)
     
  • USD/JPY

    135.3810
    -0.4610 (-0.34%)
     
  • BTC-USD

    19,963.00
    -374.12 (-1.84%)
     
  • CMC Crypto 200

    432.56
    -7.47 (-1.70%)
     
  • FTSE 100

    7,025.47
    -207.18 (-2.86%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

What Type Of Shareholders Own The Most Number of TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Every investor in TherapeuticsMD, Inc. (NASDAQ:TXMD) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

TherapeuticsMD is a smaller company with a market capitalization of US$299m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about TherapeuticsMD.

View our latest analysis for TherapeuticsMD

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About TherapeuticsMD?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that TherapeuticsMD does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at TherapeuticsMD's earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in TherapeuticsMD. BlackRock, Inc. is currently the largest shareholder, with 5.9% of shares outstanding. With 4.9% and 4.7% of the shares outstanding respectively, Deerfield Management Company, L.P. and Robert Finizio are the second and third largest shareholders. Robert Finizio, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of TherapeuticsMD

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

We can see that insiders own shares in TherapeuticsMD, Inc.. In their own names, insiders own US$20m worth of stock in the US$299m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public holds a 48% stake in TherapeuticsMD. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with TherapeuticsMD (at least 2 which are a bit unpleasant) , and understanding them should be part of your investment process.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.